NCT05909488Not yet recruitingPhase 2/3
Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II
Role of Umbilical Cord-derived Stem Cell Transplantation and Conditioned Medium to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II
Source: ClinicalTrials.gov · Last updated 25 Feb 2026
Brief summary (registry, in English)
The study will perform UC-MSCs and CM transplantation. There are two groups with different dosages. The first group will be transplanted with 1.5 million cells, meanwhile, the second group is 5 million cells. Each group consists of 30 subjects. All groups will be transplanted via the peribulbar route. All groups will be observed until six months.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 14 Mar 2023
- Start date
- May 2026
- Primary completion date
- Jul 2027
- Lead sponsor
- PT. Prodia Stem Cell Indonesia
- Diseases
- Retinitis pigmentosa
- NCT number
- NCT05909488
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 30
- From May 2026 to the primary completion date, Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Under immunosuppressive treatment or other drugs that can affect the growth of transplanted stem cells
Other illness
- Positive result of HIV test
- Have a history of eye tumors
- Have another eye disease such as diabetic retinopathy, uveitis, cataract, and glaucoma
Other
- Pregnant or nursing women
- Do not come to control according to the schedule determined by the researcher (loss to follow up)
Who the study is looking for
- Visus more than 20/100
- Have more than 0.68 uV on conical receptor cell amplitude checked by ERG
- Visual field equivalent diameter more than 10o
- Willing to sign informed consent as research subjects
- Willing to do the peribulbar injection with mesenchymal stem cells isolated from umbilical cord tissue
- Willing to do visual field checks with Humphrey's perimetry, vision tests with Snellen boards, Optical Coherent Tomography (OCT) examinations, electroretinogram examinations, and fill out a quality of life questionnaire
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Rsup Dr Sardjito Coordinator of this site? Confirm its status | Yogyakarta | Indonesia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.